Table 3.
Patients’ characteristics at the last follow-up.
| All n = 201 |
EMB-Proven Myocarditis n = 49 |
Clinically Suspected Myocarditis n = 152 |
p-Value | |
|---|---|---|---|---|
| Duration of the follow-up (months) | 32 (14–61) | 42 (17–64) | 30 (14–57) | 0.16 |
| Dead or transplanted | 1 (0%) | 1 (2%) | 0 (0%) | 0.074 |
| NYHA class, I | 188 (94%) | 40 (85%) | 148 (97%) | 0.001 |
| II–IV | 11 (6%) | 7 (15%) | 4 (3%) | |
| Sinus rhythm | 187 (96%) | 40 (87%) | 147 (99%) | <0.001 |
| Atrial fibrillation | 4 (2%) | 4 (9%) | 0 (0%) | |
| Beta-blockers | 63 (31%) | 33 (67%) | 30 (20%) | 0.002 |
| Ivabradine | 6 (3%) | 4 (8%) | 2 (1%) | 0.014 |
| ACE inhibitors * | 59 (32%) | 20 (44%) | 39 (27%) | 0.033 |
| ARB † | 10 (9%) | 8 (22%) | 2 (3%) | <0.001 |
| Amiodarone | 2 (1%) | 2 (4%) | 0 (0%) | 0.012 |
| Anticoagulants * | 7 (4%) | 7 (16%) | 0 (0%) | <0.001 |
| LV end-diastolic diameter, mm ‡ | 49.4 ± 6.3 | 52.1 ± 8.8 | 48.6 ± 5.1 | 0.005 |
| Left atrial volume, mL/mq § | 23.3 ± 10.1 | 26.0 ± 13.5 | 22.0 ± 7.6 | 0.32 |
| LVEDVi, mL/mq ? | 59 ± 17 | 69 ± 28 | 56 ± 11 | <0.001 |
| LVEF, % # | 62.4 ± 8.1 | 57.4 ± 11.3 | 64.0 ± 6.0 | <0.001 |
| RVEDA, cm ‡ | 18.5 ± 4.6 | 18.8 ± 6.5 | 18.5 ± 3.9 | 0.50 |
| RVFAC, % ** | 48.9 ± 8.0 | 48.3 ± 10.1 | 49.2 ± 7.2 | 0.68 |
Data are n (%), mean ± SD, or median (IQR). ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blockers; for other abbreviations see Table 1. Data available in * 187, † 110, ‡ 189, § 108, ? 195, # 198, ** 188 patients.